About Bionxt
Bionxt is a publicly listed company based in Vancouver (Canada) founded in 2018. Drug formulations and delivery systems for diseases are developed. Its chief executive, as recorded, is Hugh Rogers. Its focus areas include Life Sciences, Drug Delivery, Diversified and Infectious Diseases.
Company details
Bionxt was founded in 2018 in Vancouver, Canada, within the biotechnology sector. Precision transdermal and oral dissolvable drug delivery formulations are developed, alongside rapid screening tests for infectious diseases and oral health. Clinical evaluations of active pharmaceutical ingredients for neurological applications are conducted. Operations center on improving drug accessibility, with Vektor provided as a formulation for efficient delivery of approved neurological medications.
- Headquarters Vancouver, Canada
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website bionxt.com
- Social LinkedIn X Instagram
- Legal Name Bionxt Solutions Inc
- Net Profit-$5.13 M (USD)-32.27as on Dec 31, 2025
- EBITDA-$4.41 M (USD)-34.95as on Dec 31, 2025
- Latest Funding Round$1.43M (USD), Post-IPO
Jun 2026
Funding Insights of Bionxt
- Total Rounds 13
- Last Round Post-IPO — $1.43M
- First Round $1.51M
(Feb 2020)
Latest 10 of 13 funding rounds of Bionxt with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2026 | $1.43M | Post-IPO | – | – | – |
| Feb 2025 | $1.74M | Post-IPO | – | – | – |
| Jan 2025 | $138,858 | Post-IPO | – | – | – |
| Jan 2025 | $620,081 | Post-IPO | – | – | – |
| Jan 2025 | $288,837 | Post-IPO | – | – | – |
| Dec 2024 | $971,880 | Post-IPO | – | – | – |
| Nov 2024 | $203,310 | Post-IPO | – | – | – |
| Aug 2023 | $1.09M | Post-IPO | – | – | – |
| Mar 2023 | $1.47M | Post-IPO | – | – | – |
| Dec 2022 | $2.81M | Post-IPO | – | – | – |
People of Bionxt
2 people are tracked at Bionxt (2 in leadership).
| Name | Role | Group |
|---|---|---|
Thomas Beckert | Managing Director | Leadership |
Hugh Rogers | CEO | Leadership |
Complete people profiles for Bionxt
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Bionxt
Bionxt is a publicly listed company on the CSE with ticker symbol BNXT in Canada, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date26 Nov 2019
- Listed onOTCMKTS: BNXTF
- Listed entityBioNxt Solutions Inc
- Exchange sectorHealth technology
- ISINCA0909741062
- Share price0.30 CAD (-7.69% on the day) · 2026-10-13
- Market capitalisation40,827,948.00 CAD
- Volume (last session)44,500
Financials of Bionxt
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -7.0M CAD | -6.0M CAD | |
| 2024 | 26,980 CAD | -5.3M CAD | -4.5M CAD |
| 2023 | 372,250 CAD | -7.7M CAD | -6.2M CAD |
| 2022 | 297,440 CAD | -12.4M CAD | -6.4M CAD |
| 2021 | 286,500 CAD | -20.6M CAD | -15.4M CAD |
Detailed financial statements for Bionxt
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Bionxt
4 dated milestones of Bionxt across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Bionxt is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $1.5M.
- Funding Latest funding round, Post-IPO, of $1.4M.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bionxt
Complete news archive for Bionxt
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bionxt
Bionxt was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Bionxt is headquartered in Vancouver, Canada. It is registered at Vancouver, British Columbia, Canada.
Hugh Rogers is the CEO of Bionxt, as recorded in our data.
Bionxt was founded in 2018 in Vancouver, Canada, within the biotechnology sector. Precision transdermal and oral dissolvable drug delivery formulations are developed, alongside rapid screening tests for infectious diseases and oral health. Clinical evaluations of active pharmaceutical ingredients for neurological applications are conducted. Operations center on improving drug accessibility, with Vektor provided as a formulation for efficient delivery of approved neurological medications.
Yes, Bionxt is publicly traded on CSE under the ticker symbol BNXT.